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a b s t r a c t
Background: Mitral stenosis (MS) is associated with prolonged inter- and intra-atrial elec-
tromechanical delays and increased P-wave dispersion, which are markers of atrial ﬁbrilla-
tion (AF) risk. This study was conducted to assess the immediate effect of successful
percutaneous transvenous mitral commissurotomy (PTMC) on these parameters.
Methods: This single center observational study included 25 patients with severe MS (aged
34.1  7.1 years, with mean mitral valve area (MVA) of 0.74  0.13 cm2), in sinus rhythm, who
underwent successful PTMC at our hospital. P-wave dispersion (PWD) was calculated by
subtracting minimum P-wave duration (Pmin) from maximum P-wave duration (Pmax),
measured on a 12-lead surface ECG obtained from each patient in supine position at a
paper speed of 50 mm/s and 20 mm/mV. Inter-atrial (AEMD), left intra-atrial (L-IAEMD), and
right intra-atrial (R-IAEMD) electromechanical delays were measured on tissue Doppler
imaging. PTMC was performed using the standard Inoue Balloon technique. All these
parameters were evaluated and compared before and 24–48 h after PTMC.
Results: Successful PTMC led to signiﬁcant reduction in AEMD ( p < 0.001), L-IAEMD
( p < 0.001), and R-IAEMD ( p < 0.001). There were no changes in Pmax, Pmin, and PWD
immediately after PTMC.
Conclusions: Successful PTMC has a favorable early impact on inter- and intra-atrial elec-
tromechanical delays, which are considered as novel parameters of atrial electromechanical
remodeling in MS patients. Prospective large-scale studies are required to conﬁrm whether
improvement in these markers translates into reduced long-term AF risk.
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Rheumatic mitral stenosis (MS) is an acquired progressive
form of valvular heart disease, characterized by diffuse
thickening of mitral valve leaﬂets, fusion of commissures
and shortening and fusion of chordae tendinae. The combi-
nation of mitral valve disease and atrial inﬂammation,
secondary to rheumatic carditis leads to left atrial (LA) dilation,
ﬁbrosis of atrial wall, and disorganization of atrial muscle
bundles.1 These structural changes lead to electrical inhomo-
geneity, non-uniform conduction velocities, and inhomogen-
ous refractory periods within the atrial myocardium.2,3 The
resultant electrical dyssynchrony and electromechanical
dysfunction are associated with increased risk of atrial
ﬁbrillation (AF).4
Several electrocardiographic and echocardiographic
markers reﬂecting the electrophysiological and electrome-
chanical abnormalities of atria prone to develop AF have
been studied with an idea of early identiﬁcation of
patients who are susceptible to develop AF. Increased
maximum P-wave duration (Pmax) on surface ECG has been
reported to be associated with left atrial size and risk of
developing AF.5,6 P-wave dispersion (PWD) is an ECG marker
of non-uniform and heterogeneous atrial conduction with
ECG leads of different orientation.5 It has been deﬁned as the
difference between maximum and minimum P-wave dura-
tion (Pmax and Pmin). Previous investigations have shown
that Pmax and PWD are increased in patients with rheumatic
MS.7,8
Atrial electromechanical delay (AEMD) has been deﬁned as
the temporal delay between the detected onset of electrical
activity (P-wave on ECG) and the realization of force in the
atrial myocardium (onset of A0 wave on tissue Doppler
imaging (TDI).9 Advances in TDI technology have facilitated
the detection of atrial mechanical activity from different
atrial regions with high temporal resolution and allowed
calculation of inter- and intra-atrial electromechanical
delays.10–12 Prolonged AEMD is considered as a novel marker
of atrial electromechanical remodeling and has been associ-
ated with increased AF risk in various disease states including
MS.9,13–15
Percutaneous transvenous mitral commissurotomy (PTMC)
is currently the treatment of choice for patients with
symptomatic severe MS and favorable valve morphology.
Successful PTMC leads to increase in mitral valve area (MVA),
cardiac index, and decrease in transmitral diastolic pressure
gradient, left atrial pressure, left atrial volume, and pulmonary
artery pressures.16,17 It also leads to sustained improvement in
the functional class of the patients.18,19 Recent studies have
demonstrated that reduction in left atrial pressure and relief of
chronic stretch following PTMC reverses left atrial direction-
dependent conduction abnormalities, thus increasing the
chances of MS patients retaining their normal sinus
rhythm.20–22 This study was conducted with an aim of
studying the immediate effect of successful PTMC on inter-
and intra-atrial electromechanical delays and PWD in patients
with severe rheumatic MS, in normal sinus rhythm. To the best
of our knowledge, there is only one such study published in
literature so far.232. Methods
2.1. Study design
This was a hospital-based prospective, non-randomized,
observational study.
2.2. Study population
The study population included 25 consecutive patients
admitted in our hospital with symptomatic severe MS [NYHA
class II–IV, MVA of ≤1 cm2 by planimetry, pressure half time
(PHT) ≥ 220 ms, and/or mean transmitral diastolic gradient
(MDG) of ≥10 mmHg],24–26 in normal sinus rhythm, with
favorable valve morphology (Wilkins's score ≤ 8, no or mild
mitral regurgitation, and no commissural calciﬁcation or LA
thrombus)27,28 who underwent a successful PTMC (immediate
post-procedural MVA of ≥1.5 cm2 or ≥50% increase from pre-
procedural MVA, and no more than moderate mitral regurgi-
tation after the procedure).29,30 Exclusion criteria included: (i)
Documented history or peri-procedural occurrence of AF or
any other sustained arrhythmia. (ii) Signiﬁcant involvement of
valves other than mitral valve (aortic valve, pulmonary valve,
tricuspid valve) or evidence of mitral annular calciﬁcation on
echocardiography. (iii) Known history or clinical evidence of
coronary artery disease, primary cardiomyopathy, left ven-
tricular (LV) dysfunction, conduction abnormalities, pericar-
ditis, thyroid dysfunction, anemia, renal failure (serum
creatinine of >1.5 mg/dl), pulmonary disease, hypertensive
cardiovascular disease, systemic inﬂammatory disease. (iv)
Exposure to any known cardiotoxin (i.e. doxorubicin chemo-
therapy, ethanol, etc.), electrolyte imbalance, use of medica-
tions known to affect atrial conduction (i.e. digitalis,
antiarrythmic drugs), and patients on pacemakers. (v) Clinical
or laboratory evidence of rheumatic activity in preceding 6
months. (vi) Indiscernible P-waves in more than four leads on
the baseline 12-lead ECG. (vii) Past history of any mitral valve
intervention (PTMC, closed mitral valvotomy, open mitral
valvotomy) or other cardiac surgeries.
2.3. Consent and ethical issues
An informed consent was obtained from each patient after
explaining the study in detail. The study was cleared by the
Institutional Ethics Committee.
2.4. Pre-procedural evaluation
A detailed clinical history was obtained and complete physical
examination of each patient was performed after admission.
Baseline investigations including complete blood count,
serum biochemistry, coagulation proﬁle, serum electrolytes,
and chest X-ray were performed one day prior to procedure.
2.5. Electrocardiogram (ECG)
On the morning of the day of procedure, a 12-lead surface ECG
of each patient in supine position at a paper speed of 50 mm/s
and 20 mm/mV was obtained to calculate the pre-procedural
P-wave durations and PWD. The P-wave durations were
Fig. 1 – Measurement of PA0lateral by Tissue Doppler Imaging
(TDI).
Fig. 2 – Measurement of PA0septal by Tissue Doppler Imaging
(TDI).
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details of the patient, using calipers and magnifying lens
(tenfold magniﬁcation) to deﬁne the electrocardiographic
deﬂections. The onset of the P-wave was deﬁned as the
junction between the isoelectric line and the beginning of P-
wave deﬂection. The offset of P-wave was deﬁned as the
junction between the end of the P-wave deﬂection and the
isoelectric line. The time internal between the onset and
offset of P-wave was the P-wave duration. In each ECG lead, P-
wave duration was measured for three consecutive P-waves
and the mean of three measurements was considered to be
the P-wave duration of that lead. P-wave duration was
measured in all 12-ECG leads. Patients with indiscernible P-
waves in more than four leads on the baseline 12-lead ECG
were excluded from the study. The longest P-wave duration
measured on any of the 12 ECG leads was deﬁned as the P
maximum (Pmax) and the shortest P-wave duration on any
lead was deﬁned as the P minimum (Pmin). The difference
between Pmax and Pmin was calculated and deﬁned as
PWD = Pmax  Pmin. After 24–48 h of the successful PTMC
procedure, a similar ECG was obtained to calculate the post-
procedural Pmax, Pmin, and PWD.
2.6. Echocardiography
A comprehensive pre-procedural echocardiographic exami-
nation of each patient was carried out in the morning of the
day of procedure, using a commercially available cardiac
ultrasound scanner equipped with 2.5 and 3.5 MHz transdu-
cers (Aloka, Prosound, SSD a-110, South Korea), by an
experienced cardiologist who was blinded to the clinical
details and results of other investigations of the patient. Each
patient was examined in the left lateral decubitus and supine
position by precordial 2-dimensional, M-mode, Doppler, and
tissue Doppler echocardiography according to the criteria of
American Society of Echocardiography.31,32 During the
echocardiographic examination, a 1-lead ECG was recorded
continuously. An average of three consecutive cycles was
analyzed for each parameter. Left ventricular end-systolic
and end-diastolic diameters (LVIDS and LVIDD) and left atrial
(LA) end-systolic diameter were measured by M-mode
imaging in the parasternal long axis view. LV end-systolic
volume (LVESV), LV end-diastolic volume (LVEDV), and
ejection fraction (LVEF) were estimated by Simpson's rule
in the apical 4-chamber view. MS was quantiﬁed by
estimation of MVA by 2D planimetry in parasternal short
axis view and by the pressure half time method in the apical
4-chamber view using continuous wave (CW) Doppler.25,26
Peak and mean transmitral diastolic pressure gradients (PDG
and MDG) were measured by continuous wave Doppler in the
apical four chamber view. Mitral valve morphology and the
sub-valvular apparatus were assessed by 2D imaging, and
Wilkins's score was calculated.27,28 Pulmonary artery systolic
pressure (PASP) was calculated by adding the estimated right
atrial pressure to {(tricuspid regurgitation velocity)2  4},
measured by continuous wave Doppler in the apical four
chamber view.33 Color ﬂow Doppler imaging was used to
detect and quantify the severity of mitral regurgitation
according to the guidelines of the American Society of
Echocardiography.34LA volume was calculated by the modiﬁed Simpson's
method from the apical four chamber view at end systole, and
was corrected for body surface area (BSA).35
For the assessment of inter- and intra-atrial electrome-
chanical delays, tissue Doppler echocardiography was per-
formed by activating the TDI mode of the same machine. TDI
was done with transducer frequencies of 3.5–4 MHz, adjusting
the spectral pulse Doppler signal ﬁlters until a Nyquist limit of
15–20 cm/s was reached and using the minimal optical gain.
The monitor sweep speed was set at 50–100 mm/s to optimize
the spectral display of myocardial velocities.9–15 In the apical
four chamber view, the pulsed Doppler sample volume was
placed at the level of LV lateral mitral annulus (Fig. 1), septal
mitral annulus (Fig. 2), and right ventricular (RV) tricuspid
annulus (Fig. 3). Special effort was made to align the pulsed
wave cursor in order to keep the Doppler angle of incidence as
close to 08 as possible to the direction of these walls. Time
interval from the onset of P-wave on surface ECG to the
beginning of late diastolic wave (A0 wave) on TDI, named as
Fig. 3 – Measurement of PA0tricuspid by Tissue Doppler
Imaging (TDI).
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mitral annulus (PA0septal), and RV tricuspid annulus (PA
0
tricuspid),
respectively.9–15 The difference between lateral PA0 and tricus-
pid PA0 (PA0lateralPA0tricuspid) was deﬁned as inter-atrial electro-
mechanical delay (AEMD); difference between septal PA0 and
tricuspid PA0 (PA0septalPA0tricuspid) was deﬁned as right intra-
atrial electromechanical delay (R-IAEMD); and the difference
between lateral PA0 and septal PA0 (PA0lateralPA0septal) was deﬁned
as left intra-atrial electromechanical delay (L-IAEMD).9–15
Immediately after the PTMC procedure, a repeat echocar-
diogram was performed to assess the post-procedural MVA,
presence and severity of mitral regurgitation, peak and mean
transmitral diastolic pressure gradients, PASP, and to deﬁne
the success of procedure as described previously.29,30 All
patients, in whom PTMC was successful, underwent a repeat
echocardiographic evaluation 24–48 h after the procedure for
the measurement of post-procedural LA diameter; LV dimen-
sions, volumes and EF; LA volume; and inter- and intra-atrial
electromechanical delays.
2.7. PTMC procedure
PTMC was performed using a standard trans-septal approach
with an Inoue balloon.36 Pre- and post-procedural catheteri-
zation data were not included in this study.
2.8. Collection and recording of data
All the patient data including demographic, clinical, diagnostic
data as well as pre- and post-procedural electromechanical
parameters, procedural outcome, complications, and dis-
charge diagnosis were recorded on a specially pre-designed
patient record form.
2.9. Statistical analysis
Statistical analysis was performed by SPSS software package
(version 20.0, SPSS Inc, Chicago, Illinois, USA). All continuous
variables were expressed as mean  SD, and categoricalvariables were reported as frequency and percentages.
Pearson's correlation coefﬁcients were used to assess the
strength of relationship between continuous variables. Paired
t-test was used to study the difference of means of various
continuous variables. Statistical signiﬁcance was deﬁned as a p
value of <0.05.
3. Results
The initial study population included 30 patients of
symptomatic severe MS, in normal sinus rhythm, who
fulﬁlled the other inclusion criteria before the procedure. Out
of these, 5 patients were excluded from the study after PTMC
(2 patients did not give consent for the study, 1 patient had a
failed trans-septal puncture, 1 patient developed severe
post-procedural mitral regurgitation, and 1 patient devel-
oped peri-procedural AF which reverted to sinus rhythm
after DC cardioversion). Final study sample consisted of the
remaining 25 patients. Immediate procedural success rate
was 93.3% (peri-procedural AF was not considered to be a
procedural failure).
3.1. Patient characteristics
Mean age of the patients was 34.1 years, ranging from 21 to 45
years. Among the 25 patients recruited in the study sample, 7
(28%) were male while 18 (72%) patients were female. Mean
body surface area of the patients was 1.45 m2, ranging from
1.29 m2 to 1.75 m2.
3.2. Pre-PTMC parameters
3.2.1. Routine echocardiographic parameters
Baseline echocardiographic parameters of the patients were as
follows: LA diameter – 4.82  0.51 cm; LVIDD – 4.39  0.34 cm;
LVIDS – 2.73  0.36 cm; LVEDV – 60.99  10.79 ml/m2; LVESV –
19.37  5.77 ml/m2; LVEF – 68.52  5.48%; Wilkins score – 6.04
 1.27; MVA-2D – 0.74  0.13 cm2; MVA-PHT – 0.79  0.14 cm2;
PDG – 27.76  6.25 mmHg; MDG – 15.60  4.23 mmHg; PASP –
58.68  13.14 mmHg; and LA volume – 79.0  12.30 ml/m2.
3.2.2. P-wave durations and PWD
Baseline P-wave durations were: Pmax – 136.40  13.19 ms; and
Pmin – 91.60  12.48 ms. PWD was 44.80  5.86 ms.
3.2.3. PA0 intervals, Inter- and Intra-atrial electromechanical
delays
Baseline PA0 intervals were: PA0septal – 44.96  5.57 ms; PA0lateral –
106.24  18.48 ms; and PA0tricuspid – 32.48  4.81 ms. Inter- and
intra-atrial electromechanical delays were: AEMD – 73.76
 15.67 ms; R-IAEMD – 12.48  2.66 ms; and L-IAEMD – 61.28
 14.27 ms.
3.3. Pearson correlation analysis of inter- and intra-atrial
electromechanical delays (Table 1)
AEMD and L-IAEMD showed a positive correlation with age, LA
diameter, Wilkins score, PDG, MDG, PASP, LA volume, Pmax,
and Pmin. AEMD and L-IAEMD were negatively correlated with
Table 1 – Pearson correlation analysis of inter- and intra-atrial electromechanical delays.
Parameter AEMD R-IAEMD L-IAEMD
r p r p r p
Age 0.701 <0.001 0.419 0.037 0.691 <0.001
BSA 0.139 0.508 0.211 0.312 0.113 0.590
LA diameter 0.757 <0.001 0.445 0.026 0.749 <0.001
LVIDD 0.166 0.428 0.061 0.772 0.193 0.354
LVIDS 0.153 0.466 0.106 0.613 0.188 0.369
LVEDV 0.112 0.593 0.152 0.469 0.151 0.470
LVESV 0.133 0.525 0.166 0.428 0.177 0.396
LVEF 0.135 0.521 0.155 0.460 0.177 0.398
Wilkins score 0.564 0.003 0.338 0.099 0.556 0.004
MVA-2D 0.421 0.036 0.151 0.470 0.434 0.030
MVA-PHT 0.424 0.035 0.261 0.208 0.417 0.038
PDG 0.513 0.009 0.217 0.297 0.523 0.007
MDG 0.504 0.010 0.284 0.169 0.500 0.011
PASP 0.662 <0.001 0.309 0.132 0.669 <0.001
LA volume 0.733 <0.001 0.535 0.006 0.706 <0.001
Pmax 0.742 <0.001 0.288 0.162 0.760 <0.001
Pmin 0.616 0.001 0.277 0.180 0.625 0.001
PWD 0.358 0.079 0.060 0.776 0.382 0.060
Note: r, correlation coefﬁcient; p, p value; BSA, body surface area; LA, left atrium; LVIDD, left ventricular diastolic diameter; LVIDS, left
ventricular systolic diameter; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; LVEF, left ventricular
ejection fraction; MVA, mitral valve area-planimetry; MVA-PHT, mitral valve area – pressure half time; PDG, peak diastolic gradient; MDG, mean
diastolic gradient; PASP, pulmonary artery systolic pressure; Pmax, maximum P-wave duration; Pmin, minimum P-wave duration; PWD, P-wave
dispersion. Bold entries represent signiﬁcant p values.
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correlation with PWD. R-IAEMD showed a positive correlation
with age, LA diameter, and LA volume. There was no
signiﬁcant correlation between R-IAEMD and MVA MDG, RVSP,
Pmax, Pmin, or PWD (Table 1).
3.4. Impact of PTMC on various parameters
3.4.1. Routine echocardiographic parameters (Table 2)
Immediately after PTMC, there was a statistically signiﬁcant
decrement in LA diameter, LA volume, PDG, MDG, and PASP.
There was a statistically signiﬁcant increase in MVA-2D,Table 2 – Impact of PTMC on routine echo parameters.
Parameter Pre-PTMC (mean  SD) Post-P
LA diameter (cm) 4.82  0.51 
LA volume (ml/mm2) 79.00  12.30 
LVIDD (cm) 4.39  0.34 
LVIDS (cm) 2.73  0.36 
LVEDV (ml/m2) 60.99  10.79 
LVESV (ml/m2) 19.37  5.77 
LVEF (%) 68.52  5.48 
MVA-2D (cm2) 0.74  0.13 
MVA-PHT (cm2) 0.79  0.14 
PDG (mmHg) 27.76  6.25 
MDG (mmHg) 15.60  4.23 
PASP (mmHg) 58.68  13.14 
Note: LA, left atrium; LVIDD, left ventricular diastolic diameter; LVIDS, le
volume; LVESV, left ventricular end systolic volume; LVEF, left ventricu
mitral valve area – pressure half time; PDG, peak diastolic gradient; MDG
Bold entries represent signiﬁcant p values.MVA-PHT, LVIDD, and LVEDV. There was no signiﬁcant change
in LVIDS, LVESV, and LVEF after PTMC (Table 2).
3.4.2. P-wave durations and PWD (Table 3)
There was no change in Pmax, Pmin, and PWD in the immediate
post-PTMC phase (Table 3).
3.4.3. PA0 intervals, inter- and intra-atrial electromechanical
delays (Table 4)
There were statistically signiﬁcant reductions in PA0septal,
PA0lateral, PA
0
tricuspid intervals, AEMD, R-IAEMD, and L-IAEMD
in the immediate post-PTMC phase (Table 4).TMC (mean  SD) Difference (mean) p-Value
4.46  0.58 0.36 <0.001
67.95  14.93 11.05 <0.001
4.54  0.29 0.15 <0.001
2.78  0.27 0.05 0.136
65.82  8.97 4.83 <0.001
20.15  4.44 0.78 0.193
69.56  4.44 1.04 0.143
1.77  0.25 1.03 <0.001
1.80  0.22 1.01 <0.001
13.12  4.43 14.64 <0.001
6.40  1.91 9.20 <0.001
45.92  11.56 12.76 <0.001
ft ventricular systolic diameter; LVEDV, left ventricular end diastolic
lar ejection fraction; MVA, mitral valve area-planimetry; MVA-PHT,
, mean diastolic gradient; PASP, pulmonary artery systolic pressure.
Table 3 – Impact of PTMC on P-wave durations and PWD.
Parameter Pre-PTMC (mean  SD) Post-PTMC (mean  SD) Difference (mean) p-Value
Pmax (ms) 136.40  13.19 136.40  13.19 0.00 1.000
Pmin (ms) 91.60  12.48 91.60  12.48 0.00 1.000
PWD (ms) 44.80  5.86 44.80  5.86 0.00 1.000
Note: Pmax, maximum P-wave duration; Pmin, minimum P-wave duration; PWD, P-wave dispersion.
Table 4 – Impact of PTMC on PA0 intervals, inter- and intra-atrial electromechanical delays.
Parameter Pre-PTMC (mean  SD) Post-PTMC (mean  SD) Difference (mean) p-Value
PA0septal ðmsÞ 44.96  5.57 42.08  5.67 2.88 <0.001
PA0lateral ðmsÞ 106.24  18.48 89.28  15.00 16.96 <0.001
PA0tricuspid ðmsÞ 32.48  4.81 31.36  4.72 1.12 0.016
AEMD (ms) 73.76  15.67 57.92  11.73 15.84 <0.001
R-IAEMD (ms) 12.48  2.66 10.72  2.51 1.76 <0.001
L-IAEMD (ms) 61.28  14.27 47.20  10.89 14.08 <0.001
N o t e : PA0septal; PA
0 interval at septal mitral annulus; PA0lateral; PA
0 interval at lateral mitral annulus; PA0tricuspid; PA
0 interval at tricuspid
annulus; AEMD, atrial electromechanical delay; R-IAEMD, right intra-atrial electromechanical delay; L-IAEMD, left intra-atrial electromechanical
delay. Bold entries represent signiﬁcant p values.
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The main ﬁndings of our study were:
1. Successful PTMC led to a statistically signiﬁcant decrease in
inter- and intra-atrial electromechanical delays.
2. There was no change in P-wave durations or P-wave
dispersion immediately after PTMC.
3. Inter- and intra-atrial electromechanical delays showed a
strong positive correlation with P-wave durations but not
with PWD.
In rheumatic MS, the left atrial anatomy, physiology, and
electrophysiology are adversely affected secondary to in-
creased left atrial afterload and direct involvement of left
atrium by rheumatic carditis.1–3,37 These changes are associ-
ated with an increased risk of development of AF which
signiﬁcantly increases the long-term mortality and morbidity
of these patients.4,37,38
Introduced ﬁrst in 1984 by Inoue et al.,36 PTMC has currently
become the treatment of choice in patients with moderate to
severe MS, with favorable valve morphology, who are
symptomatic or have new onset AF or signiﬁcant pulmonary
hypertension.39 Over the past three decades, extensive clinical
experience has established the safety and efﬁcacy of this
procedure in both short and long term.16–19,27–30 Some studies
have shown that PTMC has a favorable impact on long-term
incidence of AF in MS patients.20,40 In the present study, we not
only described the proven acute hemodynamic beneﬁts of
PTMC but also demonstrated its favorable effect on novel
parameters of left atrial electromechanical remodeling. We
also described the correlation of these parameters with each
other and with various clinical and hemodynamic variables.
Our study, in consistency with the previous well-estab-
lished studies, demonstrated signiﬁcant increase in MVA, LV
end-diastolic dimensions and end-diastolic volumes, andsigniﬁcant decrease in LA diameter, trans-mitral diastolic
pressure gradients and PASP immediately after PTMC.16–19,27–
30
Increased Pmax and PWD are well-known ECG markers of
non-uniform and heterogeneous atrial conduction.13 Various
studies have demonstrated their association with left atrial
size and risk of developing AF.5,6 Previous investigations have
also shown that PWD is increased in patients with rheumatic
MS.7,8 In a study conducted on patients with mild to moderate
MS, Guntekin et al. demonstrated that Pmax and PWD increase
progressively in accordance with the progression of MS.41 They
also showed that Pmax, Pmin, and PWD were signiﬁcantly
correlated with MVA, mean mitral gradient, LA size, and PASP.
Likewise, we also found that baseline Pmax and Pmin had a
signiﬁcant correlation with these parameters. Additionally, we
also demonstrated that Pmax and Pmin had positive correlation
with age, Wilkins score, and left atrial volume. These ﬁndings
suggest that increasing age and greater distortion of mitral
valve apparatus (suggestive of greater rheumatic activity
process) and larger LA volume are associated with more
severe structural changes in the left atrium, leading to greater
electrical inhomogeneity, non-uniform conduction velocities,
and inhomogeneous refractory periods within the atrial
myocardium, which manifests on the ECG as increased P-
wave duration. These observations are supported by the
ﬁndings of Kabukcu et al., who suggested that AF is a marker of
widespread rheumatic damage in patients with MS.42 Al-
though PWD was prolonged in our patients, we did not ﬁnd any
signiﬁcant correlation between PWD and other parameters.
Rezaian et al. have also made a similar observation in the
past.43 They attributed this ﬁnding to the fact that majority of
the patients in their study had mild MS and a substantial
proportion of them were on beta blockers (known to reduce
PWD).8 Since we excluded the patients with non-severe MS
and those taking beta blockers from our study, these reasons
could not explain our ﬁnding, which needs further clariﬁca-
tion. Furthermore, we did not observe any change in P-wave
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 4 6 – s 5 4S52durations and PWD in the immediate post-PTMC period. While
some authors have demonstrated an acute decrease in these
parameters after successful PTMC,7 others have found that
such regression occurs somewhat late (≥6 months) after the
procedure.44 We believe that surface ECG manifestations of
delayed and heterogeneous atrial conduction may take time to
resolve after successful relief of MS. This needs conﬁrmation
on follow-up.
AEMD is a novel, simple, and inexpensive alternative to
invasive electrophysiological studies for assessing atrial
electromechanical remodeling.9–15 Recent studies have
revealed that AEMD is prolonged in patients with paroxysmal
AF and other disease states associated with increased risk of
AF.9–15 These studies indicated that prolonged AEMD seems to
reﬂect atrial remodeling for an arrhythmogenic substrate. Ozer
et al. demonstrated that AEMD is prolonged in patients with
MS and is correlated with PWD.13 They also showed that AEMD
is related with left atrial size but not with the severity of MS.
Our study revealed that AEMD was positively correlated with
age, LA diameter, Wilkins score, trans-mitral pressure gra-
dients, pulmonary artery pressure, LA volume, Pmax, and Pmin.
Although AEMD had a positive correlation with PWD, this was
not statistically signiﬁcant in our study. Additionally, AEMD
showed a negative correlation with MVA. This was in contrast
to the observation made by Ozer et al.13 This discrepancy could
partly be explained by the fact our patients had more severe
MS compared to those included in that study (MVA – 0.74
 0.13 cm2 vs 1.5  0.36 cm2). Univariate correlations of L-
IAEMD were similar to those of AEMD, while R-IAEMD was
positively correlated with age, LA diameter, and LA volume.
These ﬁndings suggest that like P-wave duration and PWD,
inter- and intra-atrial electromechanical delays are markers of
left atrial remodeling in patients with MS and prolong
progressively with increasing age, severity of MS, and left
atrial volumes. Furthermore, a strong positive correlation
between these electrocardiographic and echocardiographic
parameters suggests their complementary role in identifying
patients at increased risk of developing AF.
We also demonstrated a signiﬁcant decrease in AEMD, L-
IAEMD, and R-IAEMD immediately after successful PTMC. Till
date, there is only one published study that has demonstrated
such a ﬁnding.23 Since we did not observe any corresponding
reductions in P-wave durations and PWD, it may indicate that
TDI is superior to surface ECG in reﬂecting the changes in
atrial electrical milieu after relief of MS. Such a speculation
needs validation by invasive electrophysiological studies.
Another interesting ﬁnding of our study was that R-IAEMD
contributed to 17% of the total AEMD before PTMC and this
contribution increased to 19% after PTMC. Thus, despite the
fact that both R-IAEMD and L-IAEMD decreased signiﬁcantly
after PTMC, the reduction in total AEMD was attributable
mainly to the decrease in L-IAEMD. This can be logically
explained to be a consequence of reduction in left atrial size
and pressure following relief of MS. The increased contribu-
tion of R-IAEMD to the total AEMD after PTMC could be
hypothesized to be secondary to right atrial volume overload
due to left to right interatrial shunt across the acquired atrial
septal defect. Whether this contribution changes after the
defect gets sealed needs to be addressed in the long-term
follow-up.5. Limitations
The main limitations of our study were as follows:
(i) This study was carried out at a single center and the study
sample was relatively small.
(ii) We only studied the immediate impact of successful
PTMC on the electrocardiographic and echocardiographic
markers of AF risk. We presently do not have any long-
term follow-up data of these patients in terms of the
changes in these parameters and their actual predictive
value with regard to the risk of development of AF. Long-
term prospective studies in larger groups of patients are
required to arrive at such deﬁnitive conclusions.
(iii) We measured the conduction times only with TDI and did
not use the gold standard, i.e. electrophysiological study to
validate our results.
(iv) Finally, it is well recognized that the development of
clinical AF is complex and depends not only on substrate
but also on other factors such as triggers and initiators.
The effect of reversal of stretch on these other factors was
not addressed by this study.
6. Conclusion
Successful PTMC has a favorable early impact on inter- and
intra-atrial electromechanical delays, which are considered as
novel parameters of atrial electromechanical remodeling in
MS patients. Prospective large-scale studies are required to
conﬁrm whether improvement in these markers translates
into reduced long-term AF risk.
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